Fulcrum Therapeutics, Inc.
FULC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680581
In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 1 sale; 154 institutions reported holding it in 13F filings for Q2 2026, worth $314.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Fulcrum Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 2 filings
- 1 insider, $1.49M in total
- Open-market sells
- 1 filing
- 1 insider, $65.7K in total
- Insiders trading
- 2
- Net value
- +$1.42M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Fulcrum Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Tang Kevin C | 10% Owner | 7,080,945Indirect | Jul 20, 2026 | 2 |
| Tang Capital Management LLC | 10% Owner | 7,080,945Indirect | Jul 20, 2026 | 2 |
| Banks Sonja | Director | – | Jul 2, 2026 | 1 |
| Dorton Katina | Director | – | Jul 2, 2026 | 1 |
| Gould Robert J | Director | 469,864 | Jul 2, 2026 | 4 |
| Haviland Kate | Director | – | Jul 2, 2026 | 1 |
| King Rachel K. | Director | – | Jul 2, 2026 | 1 |
| Geraghty James A | Director | – | Jul 2, 2026 | 1 |
| Hill Colin | Director | – | Jul 2, 2026 | 1 |
| Ezekowitz Alan | Director | 10,927 | Jul 2, 2026 | 2 |
| Lehrer-Graiwer Joshua | Director | – | May 1, 2026 | 1 |
| Musso Alan A | Chief Financial Officer | – | Feb 4, 2026 | 1 |
| Sapir Alex | See Remarks | 193,360 | Feb 4, 2026 | 1 |
| Oltmans Curtis Gale | Chief Legal Officer | 10,252 | Feb 4, 2026 | 2 |
| Tourangeau Greg | Principal Accounting Officer | 14,062 | Feb 4, 2026 | 1 |
| RA Capital Healthcare Fund LP | 10% Owner | 6,053,960Indirect | Dec 10, 2025 | 1 |
| Ra Capital Management, L.P. | 10% Owner | 6,053,960Indirect | Dec 10, 2025 | 1 |
| Kolchinsky Peter | 10% Owner | 6,053,960Indirect | Dec 10, 2025 | 1 |
| Shah Rajeev M. | 10% Owner | 6,053,960Indirect | Dec 10, 2025 | 1 |
| Collins James J. | Director | – | Jun 18, 2024 | 0 |
| Horn Patrick Taylor | Chief Medical Officer | – | Mar 20, 2024 | 0 |
| Hayes Melvin H. III | Chief Operating Officer | – | Apr 28, 2023 | 0 |
| Rajavelu Esther | Chief Financial Officer | – | Feb 13, 2023 | 0 |
| Tepper Robert I | 10% Owner | 1,962,202 | Dec 15, 2022 | 0 |
| Third Rock Ventures III, L.P. | 10% Owner | 1,962,202 | Dec 15, 2022 | 0 |
| TRV GP III, LLC | 10% Owner | 1,962,202 | Dec 15, 2022 | 0 |
| Third Rock Ventures GP III, L.P. | 10% Owner | 1,962,202 | Dec 15, 2022 | 0 |
| Arroyo Santiago | Chief Medical Officer | – | Nov 9, 2022 | 0 |
| Stuart Bryan | See Remarks | 0 | Jan 21, 2022 | 0 |
| Thomson Peter G. | VP Finance & Accounting | – | Jan 21, 2022 | 0 |
| Dunn Judith | See Remarks | – | Jan 21, 2022 | 0 |
| Morabito Christopher | Chief Medical Officer | – | Jan 21, 2022 | 0 |
| Starr Kevin P | 10% Owner | 3,962,202 | Nov 12, 2021 | 0 |
| Levin Mark J | Director, 10% Owner | 3,962,202Indirect | Nov 12, 2021 | 0 |
| Moxham Christopher | Chief Scientific Officer | 0 | Aug 12, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 (view filing)9:10 PM ET | Jul 16-17 | 4 days | Tang Kevin C and 1 other10% Owner | PPurchase | +167.6K | $3.55 | +$594.7K | +2.4%7.08M after | 2 lots |
| Jul 15, 2026 (view filing)7:50 PM ET | Jul 13-15 | 2 days | Tang Kevin C and 1 other10% Owner | PPurchase | +249.9K | $3.57 | +$891.1K | +3.8%6.91M after | 4 lots |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Ezekowitz AlanDirector | SSale | −18.0K | $3.65 | −$65.7K | −62.2%10.9K after | |
| Feb 4, 2026 (view filing) | Jan 2 | 33 days | Gould Robert JDirector | SSale | −15.0K | $10.87 | −$163.1K | −3.1%469.9K after | Amended |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Gould Robert JDirector | SSale | −15.0K | $10.72 | −$160.8K | −3.2%454.9K after | |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Oltmans Curtis GaleChief Legal Officer | SSale | −3.45K | $12.92 | −$44.6K | −25.2%10.3K after | |
| Dec 10, 2025 (view filing)4:42 PM ET | Dec 8 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −4.18M | $13.98 | −$58.4M | −40.8%6.05M after | 3 lots |
| Nov 21, 2025 (view filing) | Nov 19 | 2 days | Gould Robert JDirector | SSale | −15.0K | $11.03 | −$165.4K | −3.0%484.9K after | |
| May 9, 2025 (view filing) | May 8 | 1 day | Tourangeau GregPrincipal Accounting Officer | SSale | −498 | $5.06 | −$2.52K | −3.4%14.1K after | |
| May 9, 2024 (view filing) | May 7 | 2 days | Tourangeau GregPrincipal Accounting Officer | SSale | −236 | $7.76 | −$1.83K | −2.0%11.6K after | |
| Mar 8, 2024 (view filing) | Mar 8 | Same day | Tourangeau GregVice President, Finance | SSale | −4.88K | $11.72 | −$57.2K | −29.3%11.8K after | |
| Mar 5, 2024 (view filing) | Mar 4 | 1 day | Sapir AlexSee Remarks | PPurchase | +43.4K | $11.35 | +$492.1K | New position43.4K after | |
| May 11, 2023 (view filing) | May 10 | 1 day | Tourangeau GregPrincipal Accounting Officer | SSale | −210 | $3.31 | −$695.1 | −1.3%16.0K after | |
| Jan 24, 2023 (view filing)4:30 PM ET | Jan 20 | 4 days | RA Capital Healthcare Fund LP and 3 others10% Owner | PPurchase | +1.92M | $13.00 | +$25.0M | +19.9%11.6M after | |
| Jan 13, 2023 (view filing) | Jan 13 | Same day | Gould Robert JInterim President & CEO | SSale | −6.77K | $15.00 | −$101.5K | −1.3%499.9K after | |
| Jan 6, 2023 (view filing)4:39 PM ET | Jan 4 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | PPurchase | +180.7K | $7.28 | +$1.31M | +1.9%9.69M after | 2 lots |
| Dec 29, 2022 (view filing)5:00 PM ET | Dec 27 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | PPurchase | +4.09K | $5.99 | +$24.5K | 0.0%9.51M after | |
| Dec 21, 2022 (view filing)4:30 PM ET | Dec 19 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | PPurchase | +98.8K | $5.90 | +$582.8K | +1.1%9.50M after | |
| Dec 16, 2022 (view filing)4:41 PM ET | Dec 14-16 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | PPurchase | +2.40M | $5.44 | +$13.1M | +34.3%9.40M after | 3 lots |
| Jun 8, 2022 (view filing) | Jun 7 | 1 day | Gould Robert JDirector | SSale | −71.4K | $8.09 | −$577.9K | −12.4%506.6K after | |
| Jun 6, 2022 (view filing) | Jun 2-6 | 4 days | Gould Robert JDirector | SSale | −66.6K | $8.00 | −$532.8K | −11.6%506.6K after | 3 lots |
| Apr 11, 2022 (view filing) | Apr 7 | 4 days | Gould Robert JDirector | SSale | −5.63K | $24.02 | −$135.3K | −1.1%506.6K after | |
| Apr 5, 2022 (view filing) | Apr 1-5 | 4 days | Gould Robert JDirector | SSale | −94.3K | $24.16 | −$2.28M | −15.7%506.6K after | 3 lots |
| Aug 12, 2021 (view filing) | Aug 10 | 2 days | Moxham ChristopherChief Scientific Officer | SSale | −20.7K | $17.00 | −$352.1K | −100.0%0 after | |
| Aug 12, 2021 (view filing) | Aug 10 | 2 days | Moxham ChristopherChief Scientific Officer | SSaleCommon Stockm | −31.1K | $18.00 | −$559.3K | −100.0%0 after | |
| Aug 12, 2021 (view filing) | Aug 10-11 | 2 days | Stuart BryanSee Remarks | SSale | −60.0K | $20.42 | −$1.23M | −100.0%0 after | 2 lots |